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Abstract
Background: 3-hydroxy-3-methylglutaryl-coenzyme A lyase deficiency (HMGCLD) is an autosomal recessive disorder
of ketogenesis and leucine degradation due to mutations in HMGCL.
Method: We performed a systematic literature search to identify all published cases. Two hundred eleven patients
of whom relevant clinical data were available were included in this analysis. Clinical course, biochemical findings
and mutation data are highlighted and discussed. An overview on all published HMGCL variants is provided.
Results: More than 95% of patients presented with acute metabolic decompensation. Most patients manifested
within the first year of life, 42.4% already neonatally. Very few individuals remained asymptomatic. The neurologic
long-term outcome was favorable with 62.6% of patients showing normal development.
Conclusion: This comprehensive data analysis provides a systematic overview on all published cases with HMGCLD
including a list of all known HMGCL mutations.
Keywords: Ketogenesis, Organic aciduria, Leucine, Ketone body, Metabolic acidosis, Hyperammonemia,
Hypoglycemia, Metabolic decompensation, HMGCL, Inborn error of metabolism
Background
The mitochondrial enzyme 3-hydroxy-3-methylglutaryl-
coenzyme A lyase (HMGCL; EC 4.1.3.4) is required not
only for the catabolism of the essential branched-chain
amino acid leucine, but also for the synthesis of the ke-
tone bodies acetoacetate and 3-hydroxy-n-butyrate [1].
Ketone bodies are an important source of energy for ex-
trahepatic organs, in particular of the brain, in times of
insufficient energy supply. Consequently, episodes of
hypoglycemia and metabolic acidosis are an important
observation in HMGCL deficiency (HMGLD;
MIM246450). Due to the accumulation of characteristic
leucine metabolites HMGCLD can be diagnosed via
urinary organic acid analysis and usually is associated
with an abnormal blood acylcarnitine profile as well.
Confirmatory testing is available by enzyme activity as-
says in patient cells and by mutation analysis of the
HMGCL gene. Recently, the number of individuals with
confirmed HMGCLD has been estimated to be approxi-
mately 200 world-wide [1], but most information pub-
lished so far is from case reports and small retrospective
case series. Few studies have presented larger patient co-
horts [2–8]. Although many patients reported originate
from the Iberic peninsula and from Saudi Arabia, where
HMGCLD is the most prevalent organic aciduria,
HMGCLD is a panethnic disease. However, a compre-
hensive meta-analysis that covers all HMGCLD patients
described in the literature so far is missing.
This has prompted us to approach a systematic assess-
ment of all described patients with this ketogenesis
defect.
Methods
We performed a systematic literature search in PubMed
using the terms “3-Hydroxy-3-methylglutaryl-coenzyme
A lyase deficiency”, “3-Hydroxy-3-methylglutaryl-coA
lyase deficiency”, “HMGCL deficiency”, and “3-HMG-co-
enzyme A lyase deficiency” in order to obtain informa-
tion on the clinical course of all published patients. The
search was performed in September 2019 and was
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completed by searches in the Human Gene Mutation
Database (HGMD®) http://www.hgmd.cf.ac.uk/. This was
supplemented by patient data from literature known to
the authors due to their long-time work in the area of
ketone body metabolism. All patients with metabolically,
enzymatically and/or genetically proven HMGCLD on
whom relevant clinical information was provided in the
respective publication(s) were included in this study.
With this approach we identified a total of 211
HMGCLD patients, mainly published in case reports as
well as few case series. All cases were evaluated and ana-
lysed with a special focus on the patients’ age at onset,
number of metabolic decompensations, clinical course
including neurological outcome, treatment, residual en-
zyme activity and mutations in the HMGCL gene.
For the systematic overview on all published HMGCL
mutations, publications that contained no clinical infor-
mation were included in addition. A list of all publica-
tions included in the clinical data analysis is given in
Additional file 1: Table S1, a list of publications that
were additionally reviewed for mutations is provided in
Additional file 2: Table S2.
Accuracy of age data ranged from hours to years in
the different reports. For the calculation of median ages
years were converted to months which might lead to an
underestimation (i.e. 7 years = 84months, although the
patient might have been 7 years and 11months old). In
very few cases where only “newborn” was given for the
age at report, we used 5 days of age for the calculation.
If hours were given (“first symptoms 2 hours after birth”)
these were rounded to days.
Results
Two hundred eleven cases of HMGCLD were identified
and reviewed (Table 1, Additional file 1: Table S1).
Seventy-eight patients were female, 101 were male, and
the sex of the remaining 32 patients was not reported.
The dataset included 8 pairs of siblings, thereof one pair
of dizygotic twins. The age at last reported clinical
follow-up was provided for 155 patients and ranged
from 72 h to 40 years (median of 48 months). Forty-six
patients were of Turkish origin, 20 Portuguese, 13 Bra-
zilian of Portuguese ancestry, 19 Saudi Arabian, and 12
Spanish. All other origins accounted for 7 or less pa-
tients, and of 20 patients no ethnic or geographic origin
was reported. Information on parental consanguinity
was given in 122 cases with a consanguinity rate of 49%
(60/122). 169 (80.1%) patients were alive at the time of
report, 34 (16.1%) patients had deceased, and of 8 pa-
tients the outcome is not reported. Age at death ranged
from 72 h to 40 years (median 9.5 months, n = 26). Most
patients died due to metabolic decompensations, one of
them at the age of 24 years during her second pregnancy
[9]. One child deceased in his sleep at age 13months
with no apparent previous symptoms. One previously
asymptomatic 29-year-old patient died of septic shock
with multi-organic failure [10], one 7 month-old child
due to cardiomyopathy and arrhythmias [11].
Information on the number of metabolic decompensa-
tions was available for 171 patients. Thereof, 163 patients
(95.3%) suffered at least one metabolic crisis. In 8 patients
more than 10 acute episodes were reported. Eight patients
never had metabolic decompensations. Two of these pa-
tients were diagnosed asymptomatically by family screen-
ing [12, 13], three presented with seizures and/or
developmental delay [2, 14–16] and two were diagnosed
due to hepatomegaly and elevated plasma/serum activities
of transaminases [2, 5]. One patient presented with
macrocephaly, which was first noted at 2months, as well
as a doll-like facies with frontal bossing and depressed
nasal bridge [17]. She also displayed a slight “sun-setting”
phenomenon, tendency to opisthotonus and global devel-
opmental delay. Although this child never had a metabolic
crisis a tendency towards hypoglycemia was reported [17–
20]. One patient was diagnosed presymptomatically
through family screening, but developed an acute decom-
pensation in the third year of life [12].
Of 165 patients with acute symptoms the age at pres-
entation was reported (146 cases with exact numbers,
and 20 with some information, such as “neonatal onset”
or “presentation in the third year of life). Median age at
disease onset was 4 months (n = 146). 70/165 (42.4%)
Table 1 Clinical information on 211 published patients with HMGCL deficiency
Sex female n = 78
male n = 101
not reported n = 32
Age at last clinical follow-up median 48 months (n = 155, range: 72 h to 40 years)
Parental consanguinity 49% (60/122)
Deceased patients 16.1% (34/211)
Median age at disease onset 4 months (n = 146)
Patients with at least 1 metabolic decompensation 95.3% (163/171)
Patients with normal psychomotor development 62.6% (87/139)
Patients with developmental delay or distinct neurologic abnormalities 31.7% (44/139)
Grünert and Sass Orphanet Journal of Rare Diseases           (2020) 15:48 Page 2 of 8
patients presented neonatally, 65 (39.4%) and 13 (7.9%)
in the first and second year of life, respectively, while the
remainder of 17 patients (17/165; 10.8%) showed first
symptoms beyond the second year of life only (Fig. 1).
Within the neonatal onset group 11 patients were
already symptomatic on the first day of life. The latest
manifestation was reported in a 29-year-old patient who
died during the initial metabolic crisis due to multiorgan
failure [10]. There was often a significant delay until the
correct diagnosis could be made. In one patient it took
36 years between the onset of symptoms and the time of
diagnosis [2, 21].
Clinical symptoms of acute decompensations mainly
comprised vomiting, lethargy/ coma, tachypnea/apnoea,
seizures and moderate hepatomegaly. Few patients pre-
sented with stroke-like episodes. Common laboratory
findings were (severe) hypoglycemia, metabolic acidosis,
elevated activities of serum transaminases and hyper-
ammonemia. Transaminase activities were often only
mildly increased, but episodes of transient elevations up
to > 1000 U/l have been reported in few patients [22,
23]. One child developed an episode of liver dysfunc-
tion with massively elevated transaminase activities
(AST 4150 IU/L, ALT 2200 IU/L) at age 5 months [22],
and another patient showed an AST activity of 11,736
IU/l during a severe metabolic decompensation at age
7 months [23]. Hyperammonemia was rather mild in
most cases, however ammonia levels > 1000 μmol/L
have been described, and one patient even presented
with severe hyperammonemia of > 2000 μmol/l requir-
ing peritoneal dialysis [24].
Information on the neurologic outcome was available
on 140 patients (Fig. 2). Thereof, 87 (87/139; 62.6%)
showed normal psychomotor development without
neurologic abnormalities. One 2-year-old patient had tri-
somy 21 [25] and was therefore not included in the
analysis. In 9 patients (9/139; 6.5%) only slight abnor-
malities were reported including muscular hypotonia or
a transiently increased muscle tone, hyperactivity and
partial performance weaknesses such as dyslexia and dif-
ficulties in grammar. Forty-four patients (44/139; 31.7%)
showed developmental delay or distinct neurologic ab-
normalities. Eighteen patients were described as severely
retarded, 6 had a moderate and 4 a mild disability. In 5
cases the degree of neurologic impairment was not fur-
ther specified. Ten patients showed neurologic symp-
toms including spastic hemiparesis or tetraplegia,
distinct muscular hypotonia, impairment of vision and
hearing, cerebellar ataxia, movement disorders, tremor,
clonic movements, mild dysarthria, exaggerated deep
tendon reflexes and absence of social contact. Seizures
were reported in 13 patients (9.0%).
Imaging data (MRI or CT) were available of 60 pa-
tients. There will of course be a bias in favour of ab-
normal findings as imaging is primarily performed in
patients with neurologic symptoms. Nevertheless, it is
notable that imaging results were unremarkable in
only 2 children [2, 26]. The most common findings
were white matter changes which were uniformly
present in almost all patients. Another frequent ob-
servation was cerebral atrophy with dilatation of the
ventricular system. Abnormalities reported in a few or
Fig. 1 Age at first presentation of 165 HMGCLD patients with acute symptoms. The vast majority of patients presented within the first year of life
with neonatal onset in more than 40% of patients. The latest manifestation was observed at 29 years
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single patients comprised basal ganglia involvement,
demyelinisation, ischemic lesions, chronic subdural
hematoma, subdural hygroma and bilateral occipital
porencephaly.
In 117 cases information on dietary regimens is avail-
able. Nine of these patients (7.7%) had no dietary restric-
tions, although in one of them a low-leucine diet was
recommended. The remaining 108 patients followed a
specific diet at least temporarily. Forty-six patients (46/
105; 43.8%) were on either a low-leucine (28 patients) or
low-protein (18 patients) diet, 57 patients (57/105;
54.3%) followed a diet low in leucine/protein and fat.
Only one patient had a fat-restricted diet without pro-
tein restriction (1/105; 1%). Few patients had a self-
imposed diet already before diagnosis [13, 27–29]. In
three cases it was only stated that a diet was given, but
no details were provided. Many patients on leucine/ pro-
tein restriction received supplementation with a leucine-
free amino acid mixture. Some patients received add-
itional carbohydrate supplementation either by corn
starch or by glucose polymers. Avoidance of fasting was
usually recommended. One patient received long-term
treatment with diazoxide (25 mg/8 h) [20]. Some patients
were supplemented with bicarbonate. In some patients
the diet was relaxed at some point during childhood. For
109 patients, data on carnitine treatment was available.
In this cohort, carnitine was supplemented in 85 cases
(78%), while 24 (22%) patients received no carnitine
supplementation.
Apart from neurologic symptoms long-term complica-
tions affecting other organs seem to be rather rare.
Three patients developed dilated cardiomyopathy with
arrhythmias which were fatal in two cases [2, 11, 30],
and in one patient left ventricular noncompaction was
diagnosed [31]. Two patients were reported with pan-
creatitis, one 5-year-old girl with a single episode [31]
and one boy with recurrent episodes [22].
In 4 of 216 cases, HMCGL deficiency was reported in
association with another congenital disorder. One pa-
tient had a trisomy 21 [25], one patient was reported
with VATERL syndrome [32], and one patient had a
situs inversus totalis and gastroschisis [33]. In the fourth
patient who presented with deafness and retinitis pig-
mentosa an Usher syndrome type I, a rare autosomal re-
cessive condition of profound congenital deafness and
severe retinitis pigmentosa associated with developmen-
tal delay, was suspected [27].
A total of 8 pregnancies have been reported in 5
women [9, 34–36]. Five pregnancies resulted in healthy
offspring, while one mother who already presented with
recurrent metabolic decompensations during her first
pregnancy died during her second pregnancy at 9 weeks
of gestation due to maternal metabolic decompensation
[9]. In one patient intrauterine death occurred in the
first pregnancy at 10 weeks of gestation during maternal
metabolic decompensation, and the second pregnancy
was terminated at 6 weeks of gestation in absence of
metabolic problems [9].
Fig. 2 Cognitive development and neurologic complications in 139 HMGCLD patients. 62.6% of patients show normal development, while severe
mental disability is rather rare in this patient cohort. Neurologic symptoms were documented in 10 patients including spastic hemiparesis or
tetraplegia, distinct muscular hypotonia, impairment of vision and hearing, cerebellar ataxia, movement disorders, tremor, clonic movements, mild
dysarthria, exaggerated deep tendon reflexes and absence of social contact. Seizures were reported in 13 patients
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Fig. 3 Mutations reported for human HMGCL. a: c.27del has been demonstrated by Pospísilová et al. 2003 to lead to a frame shift [39]. This
mutation leads to a frameshift and premature stop codon after 32 amino acids without degradation of the DNA, while p.(Arg10Glyfs*24) would
be predicted. b: associated with skipping of exon 2 [15]. c: Likely to affect splicing, although not proven [40]. d: Has been named p.Val168Valfs8 by
Puisac et al. 2013; may also cause skipping of exon 5 or of exons 5 and 6 (the latter resulting in a physiological mRNA transcript according to
[41]. e: According to Buesa et al. 1996 aberrant splicing, which mostly results in skipping of exon 9, p.(Met251_Thr292del,), but to a small extent in
insertion of 17 amino acids, which precede a stop codon: p.(fs*18) [42]. Not displayed: -Pie et al. (1997) reported a 84 bp in-frame deletion on the
mRNA level leads to the loss of 28 amino acids (Val-21 to Lys-48) in the mature protein [43]. This deleted region includes the last of the leader
peptide of the precursor HL protein and 21 amino acids of the N-terminus of the mature protein. -Deletion (between intron 1 and intron 4)
NG_013061: g.9326_13806del reported by Aoyama et al. 2015 [44]. - Mutation r.61-144del identified on the RNA level only [2]. - As the skipping of
exons 5-6b skipping of exons 5–7 has been reported for a physiological alternative transcript [41]. Note: Zaferiou et al. 2007 referred to a ‘C-to-T
transition’ which actually should be c.796C > T and is indicated as such in this figure [45]. Roland et al. 2017: c.438 T > G, p.(Ser46Arg) was
corrected to p.(Ser146Arg) [37]
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Enzymatic studies have been performed in 114 pa-
tients confirming a reduced or absent HMGCL activity
in leukocytes, Epstein-Barr virus (EBV)-transformed
lymphoblastoid cells or fibroblasts in all of them.
Results of HMGCL mutation analysis were reported
for 118 patients. Mutations were identified in all 9 exons
of HMGCL and also in noncoding regions of the gene.
An overview on all mutations identified in the HMCGL
gene that were reported in the literature so far is given
in Fig. 3 (following transcription into the current no-
menclature, where required). Eighty-six patients (72.9%)
carried homozygous mutations and 24 patients (20.3%)
were compound heterozygous for variants in the
HMGCL gene. In one of the homozygous patients, pater-
nal uniparental isodisomy of chromosome 1 was con-
firmed (Aoyama 2015). In 6 patients (5.1%) only one
mutation was detected, and in 2 patients (1.7%) no mu-
tation could be identified although HMGCL activity was
clearly deficient in fibroblasts [2, 37]. The most common
HMGCL mutation was the c.109G > T, p.(Glu37*) vari-
ant that was found in a total of 36 patients (30.5%),
mostly in homozygosity (homozygous in 28 patients,
heterozygous in 8 patients). It was mostly reported in in-
dividuals originating from the geographically/ demo-
graphically linked countries Brazil, Spain, Portugal and
Morocco, but also in two Pakistani patients. The two
other common variants that were identified in 12
(10.2%) and 6 patients (5.5%), respectively, were
c.122G > A, p.(Arg41Gln) and the splice site mutation
c.876 + 1G > C. While p.(Arg41Gln) was mostly found in
individuals from Saudi Arabia, it was also noted in indi-
viduals of Turkish and Italian origin. c.876 + 1G > C is
common among Turkish patients with HMGCLD. All
other mutations were reported in less than 5 individuals.
Discussion/conclusion
This work aims at a comprehensive overview on the
clinical course, biochemical and genetic data of all pa-
tients with HMGCLD published in the literature so far.
Patients with HMGCLD typically present with acute
metabolic decompensation that may be life-threatening.
Very few patients were diagnosed with only chronic,
mainly neurologic symptoms. Interestingly, only very
few asymptomatic patients have been described although
HMGCLD is a target disease of newborn screening pro-
grams in several countries. This may of course be due to
a publication bias as asymptomatic individuals are often
not reported, and some of the individuals identified by
newborn screening were described in papers with no
further relevant clinical information and therefore not
included in this analysis.
Of the symptomatic patients 42.4% presented neo-
natally and more than 80% within the first year of life,
while manifestation beyond the first year of life was the
exception. This is compatible with the special role of ke-
tone bodies for the energy supply of the newborn. Des-
pite the often early and severe manifestation the long-
term outcome seems to be favourable with the majority
of patients showing normal cognitive development. Tak-
ing into consideration that our analysis also included pa-
tients that were diagnosed and treated as early as in the
1970s, the prognosis of patients born today may be even
better than assumed based on this cohort.
As in other rare inherited metabolic diseases no con-
trolled treatment studies are available for HMCGLD.
Therefore, no conclusions can be drawn with respect to
the necessity of a special diet or carnitine supplementa-
tion from our data although the majority of patients was
on a protein and/or fat restricted diet. Based on patho-
biochemical considerations and clinical reports the
avoidance of fasting seems to be the mainstay of therapy
in this disorder of ketogenesis. Administration of L-
carnitine may have detoxifying effects and help to avoid
secondary L-carnitine deficiency and intracellular deple-
tion of free coenzyme A [38].
Our data demonstrate that HMGCLD is a panethnic
disease, although some mutations are clustered in cer-
tain geographic areas with close connections throughout
history. Interestingly, 18 patients carrying a homozygous
mutation in HMGCL were explicitly reported to be the
offspring of a non-consanguineous union. This possibly
reflects an underestimation of parental consanguinity in
this patient cohort. In line with previous reports on pa-
tient subgroups, our comprehensive study underlines
that “genotype–phenotype correlations are difficult to
establish” in HMGCLD [2, 6].
Conclusion
Despite its often early and severe manifestation
HMGCLD seems to be associated with a favorable long-
term outcome in the majority of cases.
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